Fecal Volatile Metabolites May Constitute Valuable Non-invasive Biomarkers for IBD

Fecal Volatile Metabolites May Constitute Valuable Non-invasive Biomarkers for IBD
New research indicates that the analysis of vapors from patients’ fecal samples is a potential non-invasive tool for an early differential diagnosis of inflammatory bowel diseases (IBD), namely Crohn's disease and ulcerative colitis, through the identification of biomarkers. The research article, entitled “Investigation of fecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease,” was published in the journal Alimentary Pharmacology and Therapeutics. The diagnosis of IBD can be a complex and invasive procedure, causing disease-related disability and lower quality of life in patients, and treatment-related costs on the healthcare system. Recent research has looked into the possibility of using the assessment of metabolites as non-invasive fecal biomarkers to diagnose and tract the progression of IBD. Fecal volatile organic metabolites (VOMs), chemicals that are produced during and as a result of metabolism, can be altered due to bowel diseases and other gastrointestinal (GI) disorders. The variations in VOMs are thought to be derived from dietary habits, digestive processes and excretory variations, among others. Dysfunction in gut microbiota (dysbiosis) has also been highlighted as a potential cause for variations in VOMs, and such dysfunction is also increasingly correlated, either as a cause or a consequence, with several GI disorders including IBD. Understanding the pathological role of gut microbial in IBD and finding a way to monitor it, could provide not only
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *